UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2

Thrombosis and haemostasis, 2008-09, Vol.100 (3), p.462-468

2008

Volltextzugriff (PDF)

The Primary Erythermalgia–Susceptibility Gene Is Located on Chromosome 2q31-32

American journal of human genetics, 2001-05, Vol.68 (5), p.1277-1282

2001

Volltextzugriff (PDF)

The Paradox of Platelet Activation and Impaired Function: Platelet-von Willebrand Factor Interactions, and the Etiology of Thrombotic and Hemorrhagic Manifestations in Essential Thrombocythemia and Polycythemia Vera

Seminars in thrombosis and hemostasis, 2006-09, Vol.32 (6), p.589-604

2006

Volltextzugriff (PDF)

Acquired Thrombophilia in Pregnancy: Essential Thrombocythemia

Seminars in thrombosis and hemostasis, 2003-04, Vol.29 (2), p.205-212

2003

Volltextzugriff (PDF)

The Role of JAK2 V617F Mutation, Spontaneous Erythropoiesis and Megakaryocytopoiesis, Hypersensitive Platelets, Activated Leukocytes, and Endothelial Cells in the Etiology of Thrombotic Manifestations in Polycythemia Vera and Essential Thrombocythemia

Seminars in thrombosis and hemostasis, 2006-06, Vol.32 (4), p.381-398

2006

Volltextzugriff (PDF)

Thromboxane‐dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low‐dose aspirin as an antithrombotic agent

British journal of haematology, 1999-03, Vol.104 (3), p.438-441

1999

Volltextzugriff (PDF)

Diagnosis, etiology and management of the Budd-Chiari Syndrome: a bloodcoagulation and hepatological study on the course of the disease treated with TIPS

International angiology, 2016-02, Vol.35 (1), p.90

2016

Volltextzugriff (PDF)

Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation

Thrombosis research, 2003, Vol.111 (3), p.159-164

2003

Volltextzugriff (PDF)

The 2001 World Health Organization and Updated European Clinical and Pathological Criteria for the Diagnosis, Classification, and Staging of the Philadelphia Chromosome-Negative Chronic Myeloproliferative Disorders

Seminars in thrombosis and hemostasis, 2006-06, Vol.32 (4), p.307-340

2006

Volltextzugriff (PDF)

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

British journal of haematology, 1997-04, Vol.97 (1), p.179-184

1997

Volltextzugriff (PDF)

Immune-Mediated Etiology of Acquired von Willebrand Syndrome in Systemic Lupus Erythematosus and in Benign Monoclonal Gammopathy: Therapeutic Implications

Seminars in thrombosis and hemostasis, 2006-09, Vol.32 (6), p.577-588

2006

Volltextzugriff (PDF)

Acquired von Willebrand Syndrome: Experience from 2 Years in a Single Laboratory Compared with Data from the Literature and an International Registry

Seminars in thrombosis and hemostasis, 2002, Vol.28 (2), p.227-238

2002

Volltextzugriff (PDF)

Different Accuracies of Rapid Enzyme-Linked Immunosorbent, Turbidimetric, and Agglutination D-Dimer Assays for Thrombosis Exclusion: Impact on Diagnostic Work-Ups of Outpatients with Suspected Deep Vein Thrombosis and Pulmonary Embolism

Seminars in thrombosis and hemostasis, 2006-10, Vol.32 (7), p.678-693

2006

Volltextzugriff (PDF)

Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis

European heart journal, 2005-03, Vol.26 (6), p.567-575

2005

Volltextzugriff (PDF)

Applied Multidimensional Geological Modeling: Informing Sustainable Human Interactions with the Shallow Subsurface

1, 2021

Volltextzugriff (PDF)

Response of von Willebrand Factor Parameters to Desmopressin in Patients with Type 1 and Type 2 Congenital von Willebrand Disease: Diagnostic and Therapeutic Implications

Seminars in thrombosis and hemostasis, 2002-04, Vol.28 (2), p.111-132

2002

Volltextzugriff (PDF)

A novel type 2A von Willebrand factor mutation (V1499E) associated with variable clinical expression

Journal of pediatric hematology/oncology, 2009-04, Vol.31 (4), p.277-280

2009

Volltextzugriff (PDF)

Guidelines for the Evaluation of Intravenous Desmopressin and von Willebrand Factor/Factor VIII Concentrate in the Treatment and Prophylaxis of Bleedings in von Willebrand Disease Types 1, 2, and 3

Seminars in thrombosis and hemostasis, 2006-09, Vol.32 (6), p.636-645

2006

Volltextzugriff (PDF)

A Healthy Hemophilic Patient without Arthropathy: From Concept to Clinical Reality

Seminars in thrombosis and hemostasis, 2003, Vol.29 (1), p.005-010

2003

Volltextzugriff (PDF)

Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation

Thrombosis and haemostasis, 1996-09, Vol.76 (3), p.333-338

1996

Volltextzugriff (PDF)

The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count

British journal of haematology, 1996-06, Vol.93 (4), p.962-965

1996

Volltextzugriff (PDF)

Decreased half‐life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count

British journal of haematology, 1997-12, Vol.99 (4), p.832-836

1997

Volltextzugriff (PDF)

The 2006 → 2008 European Clinical, Molecular and Patholobiogical (2008 ECMP) Classification and the 2007 WHO Revised Criteria for Myeloproliferative Neoplasms

Journal of Hematology & Thromboembolic Diseases, 2015, Vol.3 (1)

Zwi Berneman, Jan J Michiels

2015

Volltextzugriff (PDF)

Clinical and Laboratory Features, Pathobiology of Platelet-Mediated Thrombosis and Bleeding Complications, and the Molecular Etiology of Essential Thrombocythemia and Polycythemia Vera: Therapeutic Implications

Seminars in thrombosis and hemostasis, 2006-04, Vol.32 (3), p.174-207

2006

Volltextzugriff (PDF)

1 – 25 von 391

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(353)
Mit Volltextzugriff
(324)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(317)
Life Sciences & Biomedicine
(287)
Humans
(218)
Female
(109)
Biological And Medical Sciences
(97)
Male
(96)
Hematology
(85)
Middle Aged
(83)
Adult
(69)
Aged
(66)
Medical Sciences
(66)
Cardiovascular System & Cardiology
(59)
Microbiology
(58)
Peripheral Vascular Disease
(53)
Fundamental And Applied Biological Sciences. Psychology
(45)
Biochemistry & Molecular Biology
(41)
Hematologic And Hematopoietic Diseases
(39)
Platelet Diseases And Coagulopathies
(29)
General & Internal Medicine
(28)
Adolescent
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2

The Primary Erythermalgia–Susceptibility Gene Is Located on Chromosome 2q31-32

The Paradox of Platelet Activation and Impaired Function: Platelet-von Willebrand Factor Interactions, and the Etiology of Thrombotic and Hemorrhagic Manifestations in Essential Thrombocythemia and Polycythemia Vera

Acquired Thrombophilia in Pregnancy: Essential Thrombocythemia

The Role of JAK2 V617F Mutation, Spontaneous Erythropoiesis and Megakaryocytopoiesis, Hypersensitive Platelets, Activated Leukocytes, and Endothelial Cells in the Etiology of Thrombotic Manifestations in Polycythemia Vera and Essential Thrombocythemia

Thromboxane‐dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low‐dose aspirin as an antithrombotic agent

Diagnosis, etiology and management of the Budd-Chiari Syndrome: a bloodcoagulation and hepatological study on the course of the disease treated with TIPS

Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation

The 2001 World Health Organization and Updated European Clinical and Pathological Criteria for the Diagnosis, Classification, and Staging of the Philadelphia Chromosome-Negative Chronic Myeloproliferative Disorders

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

Immune-Mediated Etiology of Acquired von Willebrand Syndrome in Systemic Lupus Erythematosus and in Benign Monoclonal Gammopathy: Therapeutic Implications

Acquired von Willebrand Syndrome: Experience from 2 Years in a Single Laboratory Compared with Data from the Literature and an International Registry

Different Accuracies of Rapid Enzyme-Linked Immunosorbent, Turbidimetric, and Agglutination D-Dimer Assays for Thrombosis Exclusion: Impact on Diagnostic Work-Ups of Outpatients with Suspected Deep Vein Thrombosis and Pulmonary Embolism

Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis

Applied Multidimensional Geological Modeling: Informing Sustainable Human Interactions with the Shallow Subsurface

Response of von Willebrand Factor Parameters to Desmopressin in Patients with Type 1 and Type 2 Congenital von Willebrand Disease: Diagnostic and Therapeutic Implications

A novel type 2A von Willebrand factor mutation (V1499E) associated with variable clinical expression

Guidelines for the Evaluation of Intravenous Desmopressin and von Willebrand Factor/Factor VIII Concentrate in the Treatment and Prophylaxis of Bleedings in von Willebrand Disease Types 1, 2, and 3

A Healthy Hemophilic Patient without Arthropathy: From Concept to Clinical Reality

Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation

The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count

Decreased half‐life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count

The 2006 → 2008 European Clinical, Molecular and Patholobiogical (2008 ECMP) Classification and the 2007 WHO Revised Criteria for Myeloproliferative Neoplasms

Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work

Clinical and Laboratory Features, Pathobiology of Platelet-Mediated Thrombosis and Bleeding Complications, and the Molecular Etiology of Essential Thrombocythemia and Polycythemia Vera: Therapeutic Implications

Suchergebnisse filtern